4 not yet recruiting. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Not yet recruiting 4 |
Follow OLN324: new trials by email Literature Review of OLN324 trials Research Report on OLN324
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-02) OLN324, Aflibercept - Diabetic Macular Edema (DME) | Phase 3 | Not yet recruiting | Ollin Biosciences, Inc. | 450 | 2026-10-15 | 2026-09-25 |
| Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-03) OLN324, Aflibercept - Diabetic Macular Edema (DME) | Phase 3 | Not yet recruiting | Ollin Biosciences, Inc. | 450 | 2026-10-15 | 2026-09-25 |
| Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05) OLN324, Ranibizumab - Wet Age-related Macular Degeneration | Phase 3 | Not yet recruiting | Ollin Biosciences, Inc. | 400 | 2026-10-15 | 2026-09-11 |
| Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04) OLN324, Aflibercept - Wet Age Related Macular Degeneration | Phase 3 | Not yet recruiting | Ollin Biosciences, Inc. | 500 | 2026-10-15 | 2026-09-11 |
Diabetic Retinopathy (2) · Macular Degeneration (2)